User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

Interactions with Platform & by Email *

INTERACTIONS

Unique # Participated *

PARTICIPANTS

Responses Validated *

VALIDATIONS

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

T
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
1. Angiogenesis Inhibitors.....I-3
  
   2. Angiogenesis Stimulators.....I-4  
   Angiogenesis: In the Spotlight.....II-1
Angiogenesis: A Preview.....II-1
1$100
   Angiogenesis Makes Inroads: A Retrospect.....II-2
Angiogenesis: Ushering-In a New Era.....II-2
1$100
   Angiogenesis: Fact File.....II-31$100
   Milestones in Research Achieved Over the Years.....II-41$100
   Anti-Angiogenic Drugs Market – An Overview.....II-5
Angiogenic Inhibitors Market to Surge.....II-5
The Long Journey for Anti-Angiogenesis Therapies.....II-5
1$100
   Approved Anti-Angiogenesis Drugs in the Market.....II-6
Select FDA-Approved Anti-Angiogenic Drugs/ Therapeutics In Oncology By Type
  Monoclonal Antibody Therapies.....II-6
1$100
   Small Molecule Tyrosine Kinase Inhibitors.....II-71$100
   Inhibitors of mTOR.....II-8
Other Anti-Angiogenic Agents.....II-8
1$100
   Leading Drugs in the Market.....II-9
Avastin Leads the Fray.....II-9
Table 1: Select Leading Drugs in the Global Anti-Angiogenesis Market: Annual Sales in US$ Million for Years 2008 & 2009 (includes corresponding Graph/Chart).....II-9
1$350
   An Overview of Select Leading Drugs.....II-10
Avastin.....II-10
1$100
   Survival Benefit Conferred by Avastin.....II-111$100
   Mechanism of Action.....II-12
General Mode of Delivery.....II-12
Side Effects Elicited on Administering Avastin.....II-12
ERBITUX™ (Cetuximab).....II-12
1$100
   Regulatory Approvals.....II-13
Erbitux in Head and Neck Cancer.....II-13
1$100
   Glivec/Gleevec (imatinib mesylate).....II-14
Herceptin (Tractuzumab).....II-14
Sutent (Sunitinib).....II-14
Other Regulatory Approvals.....II-14
1$100
   Sunitinib in Various Indications.....II-15
Sunitinib in Renal Cell Carcinoma (RCC).....II-15
Sutent in Gastrointestinal Stromal Tumors (GIST).....II-15
1$100
   Cost Related Issues.....II-16
Tarceva (Erlotinib).....II-16
Other Regulatory Approvals.....II-16
Thalomid® (Thalidomide).....II-16
1$350
   Table 2: Thalomid – Percentage Breakdown Based on Relative Oncology Application (includes corresponding Graph/Chart).....II-17
Cilengitide.....II-17
Imiquimod.....II-17
1$350
   Angiogenesis Inhibitors – Pipeline Status.....II-18
Select Anti-Angiogenesis Drugs in Phase III Development.....II-18
1$100
   Select Anti-Angiogenesis Drugs in Phase II Development.....II-191$100
   Select Anti-Angiogenesis Drugs in Phase I Development.....II-201$100
   Select Approved Indications of Anti-VEGF/VEGFR Drugs.....II-21
Novel Targets for Anti-Angiogenic Activity.....II-21
Select Approved HER Receptor-Targeting Drugs.....II-21
1$100
   Select Approved m-TOR Inhibitors.....II-22
Integrins.....II-22
Select Integrin Targeting Drugs under Development.....II-22
Angiogenic Inhibitors – By Disease Application.....II-22
Cancer.....II-22
1$100
   Various Types of Cancers Targeted by Angiogenesis Inhibitors in Phase III
  Clinical Development.....II-23
Diabetic Retinopathy.....II-23
Female Reproductive Cycle.....II-23
1$100
   Psoriasis.....II-24
Inflammatory Diseases.....II-24
Table 3: Classification of Anti-Angiogenic Compounds Based on Most Commonly Targeted Indication (includes corresponding Graph/Chart).....II-24
1$350
   Angiogenesis Inhibitors in Eye Related Diseases.....II-25
Age-Related Macular Degeneration.....II-25
Wet AMD.....II-25
1$100
   Dry AMD.....II-26
Select Anti-Angiogenic Drugs Approved by FDA for Treatment of Eye Diseases.....II-26
Angiogenesis Inhibitors in Dermatology.....II-26
Select Drugs/Therapeutics with Angiogenic Mode of Action Approved by FDA for
  Dermatology.....II-26
1$100
   Cancer – The Key Target Indication for Research in Anti-Angiogeneis Drugs.....II-27
Avastin Continues to Record Robust Growth.....II-27
New Markets Offer Higher Potential for Herceptin.....II-27
Increased Use Drives Tarceva’s Growth in Developed Markets.....II-27
1$100
   Angiogenesis Inhibitors Continue to Dominate RCC Drug Market.....II-28
Votrient to Lead Renal Cell Carcinoma (RCC) Drug Market.....II-28
1$100
   Table 4: Leading Drugs in the Global Second Line Advanced Renal Cell Carcinoma Market (2010): Percentage Breakdown by Value Sales for Nexavar, Torisel, Afinitor, Avastin, and Others (includes corresponding Graph/Chart).....II-29
Clinical Benefits of Votrient Over Sutent.....II-29
1$350
   US FDA Revokes Avastin Approval for Breast Cancer.....II-301$100
   An In-depth Insight into Angiogenesis.....II-31
Angiogenesis: At a Glance.....II-31
Requisites for Angiogenesis.....II-31
1$100
   Endogenous Regulators of Angiogenesis.....II-32
Angiogenic Process: Sequence of Events.....II-32
1$100
   Angiogenesis Process in Children.....II-33
Angiogenesis Process in Adults.....II-33
The Process of Angiogenesis in Thyroid Gland.....II-33
1$100
   Angiogenic Inhibitors: Basic Framework.....II-34
Natural Inhibitors.....II-34
Thrombospondin.....II-34
Interferon.....II-34
Cryptic Inhibitors.....II-34
Other Natural Inhibitors.....II-34
1$100
   Natural Sources for Anti-Angiogenic Action.....II-35
Potential Anti-Angiogenic Drugs of Natural Origin.....II-35
Angiogenic Inhibitors: On the Verge of Attaining Superior Clinical Efficacy.....II-35
Endogenous vs Synthetic Agents.....II-35
1$100
   Angiogenesis Inhibitors: Classification Based on Source of Origin.....II-36
Anti-Angiogenic Molecules: Classification Based on Mode of Action.....II-36
Broad Overview of Anti-Angiogenic Therapies.....II-36
1$100
   Pre-Requisites for Any Drug to be an Angiogenic Inhibitor.....II-37
Specific Therapeutic Strategies of Anti- Angiogenesis Agents.....II-37
1$100
   Inhibiting Angiogenesis In Vivo.....II-38
Antiangiogenic Tumor Therapy.....II-38
Antivascular Therapy: Adding a New Dimension.....II-38
MMPs – Exhibiting Dual Role.....II-38
1$100
   Angiogenesis Inhibitors Vs Standard Chemotherapy.....II-39
Comparison Between Cytostatic Antiangiogenesis and Cytotoxic Chemotherapy.....II-39
1$100
   Proteoglycan Mixture: Therapeutic Powerhouse.....II-40
Features of VascuStatin.....II-40
Angiogenesis Inhibition Versus Cytotoxic Therapy.....II-40
Relationship Between Copper and Angiogenesis.....II-40
1$100
   Anti-Angiogenesis Action of Pencillamine.....II-41
Outline of Steps Involved in Drug Discovery for Angiogenesis.....II-41
Drug Delivery: Their Influence on Therapeutics.....II-41
2$125
   Angiogenesis Stimulators.....II-43
Growth Factors.....II-43
Angiogenic Stimulators in the Market.....II-43
Stimulators Exhibiting Profound Influence on Angiogenesis.....II-43
Vascular Endothelial Growth Factor (VEGF).....II-43
1$100
   VEGF and Their Influence on Diabetes and Diabetic Retinopathy.....II-44
Fibroblast Growth Factors (FGFs).....II-44
Basic Fibroblast Growth Factor (bFGF).....II-44
Placental Growth Factor (PlGF).....II-44
Recombinant a4 Fragment.....II-44
1$100
   Hepatocyte Growth Factor/ Scatter Factor (HGF/SF).....II-45
Angiogenin.....II-45
Platelet Derived Endothelial Cell Growth Factor.....II-45
Applications of Angiogenic Stimulators vis-à-vis Disease Perspective.....II-45
Cardiac Diseases.....II-45
Wound Healing and Burns.....II-45
Critical Limb Ischaemia.....II-45
Status of Angiogenic Inducers.....II-45
1$100
   Angiogenic Therapies for Tissue Repair & Regeneration.....II-46
Select Devices Supporting Therapeutic Angiogenesis.....II-46
Angiogenesis in Ischemic Heart.....II-46
Factors Influencing Ischemic Angiogenesis.....II-46
1$100
   Angiogenesis and CAD.....II-47
Angiogenesis in Wound Healing.....II-47
Factors Stimulating Wound Angiogenesis.....II-47
1$100
   Factors Impairing Wound Angiogenesis.....II-48
Angiogenic Therapy Vs. Conventional Therapy.....II-48
Types of Angiogensesis.....II-48
Excessive Angiogenesis.....II-48
Insufficient Angiogenesis.....II-48
Tumor Angiogenesis.....II-48
1$100
   Sequence of Actions.....II-49
Angiogenesis and Tumor Progression.....II-49
Oncogenes vis-à-vis Potential Pro-angiogenic Activities on Tumor
  Angiogenesis.....II-49
1$100
   Role of Angiogenesis in Skin Diseases.....II-50
Select Drugs & Their Targeted Application.....II-50
Analysis of Developmental Activities Between Decades.....II-50
1$100
   Role of Enzymes and Inflammatory Cells in Angiogenesis.....II-51
Angiogenic Imbalance Augments Retinal Neovascularization.....II-51
Oncogenes & VE –cadherin – A Facilitating Role.....II-51
1$100
   FDA Withdraws Approval of AstraZeneca’s NDA for IRESSA (gefitinib) Tablets.....II-52
Pfizer Obtains European Approval for SUTENT® to Treat Pancreatic NET.....II-52
Novartis Obtains FDA Approval of New Indication for Afinitor.....II-52
1$100
   FDA Approves Herceptin for Treating Metastatic Adenocarcinoma.....II-53
Roche Introduces Avastin in China.....II-53
Pfizer Japan Receives Clearance for Torisel in Japan.....II-53
GSK Obtains European Commission’s Conditional Marketing Approval for Votrient.....II-53
1$100
   FDA Approves Tarceva® for Maintenance Treatment of NSCLC.....II-54
FDA Approves GlaxoSmithKline’s Votrient.....II-54
European Commission Grants Clearance to Torisel for Mantle Cell Lymphoma.....II-54
1$100
   Genetech Receives FDA Approval for Avastin in Renal Cell Carcinoma.....II-55
FDA Approves Bevacizumab as Second Line Treatment for Glioblastoma.....II-55
Novartis Obtains FDA Approval of Afinitor for Treating Renal Cell Cancer.....II-55
1$100
   FDA Grants Clearance for Gleevec in Treatment of Gastrointestinal Stromal
  Tumor.....II-56
Celgene’s Thalidomide Pharmion™ Receives EC Clearance for Treating Multiple
  Myeloma.....II-56
Genentech Obtains FDA Approval for Avastin in Breast Cancer.....II-56
FDA Approves Nexavar for Treatment of Hepatocellular Carcinoma.....II-56
1$100
   Wyeth Receives EC Clearance for TORISEL in Advanced Renal Cell Carcinoma.....II-57
OSI and Roche Announce Approval of Tarceva® in Japan.....II-57
ImClone Obtains FDA Label Expansion for Erbitux®, as Third Line Therapy in
  mCRC.....II-57
REVLIMID® Obtains Swissmedic Authorization in Switzerland.....II-57
1$100
   REVLIMID® Receives Marketing Approval in European Union.....II-58
Wyeth Obtains FDA Clearance for Marketing Torisel.....II-58
Chugai Obtains Approval for Avastin in Japan.....II-58
1$100
   Pfizer Obtains FDA Approval for Sunitinib in Metastatic Renal Cell Carcinoma.....II-59
FDA Approves Herceptin in HER2-Overexpressing Breast Cancer Treatment.....II-59
Genentech Receives FDA Approval for Bevacizumab in Non-Small Cell Lung Cancer.....II-59
Amgen Obtains FDA Approval for Vectibix Treating mCRC.....II-59
1$100
   FDA Grants Marketing Approval for Lucentis in Wet AMD.....II-60
Celgene Obtains FDA Clearance for Revlimid in Multiple Myeloma.....II-60
1$100
   FDA Approves Bevacizumab for Second Line Treatment of Metastatic Colorectal
  Cancer.....II-61
Celgene Obtains FDA’s Accelerated Approval for THALOMID.....II-61
Celgene Obtains sNDA Approval for THALOMID from FDA.....II-61
ImClone Obtains FDA Clearance for Erbitux® in the treatment of SCCHN.....II-61
1$100
   Pfizer’s Sutent Receives FDA Nod for Treatment of Gastrointestinal Stromal
  Tumor.....II-62
Celgene Receives FDA’s Subpart H Approval for Revlimid in Myelodysplastic
  Syndromes.....II-62
1$100
   US FDA Approves OSI’s Tarceva® for Treating Pancreatic Carcinoma.....II-631$100
   Valeant to Take Over Eyetech.....II-64
Teva Acquires Cephalo.....II-64
Genentech to Carry Out Additional Trial of Avastin in Her2-negative mBC.....II-64
Pfizer to Seek regulatory Clearance for Axitinib in Europe and US.....II-64
1$100
   FDA to Withdraw Avastin’s Approval for Breast Cancer.....II-65
Eyetech Receives QTDP Grant To Develop Extended- Release Formulation of
  Macugen®.....II-65
sanofi-aventis and Regeneron to Continue VELOUR Trial as Planned.....II-65
EntreMed Enters into Financing Deal for ENMD-2076 Development.....II-65
1$100
   Chugai Pharmaceuticals Fulfills Condition for Avastin’s Approval.....II-66
Gilead Sciences to Take Over CGI Pharma.....II-66
Mersana Commences XMT-1107 Phase I Clinical Trial.....II-66
Astellas Pharma Acquires OSI Pharmaceuticals.....II-66
1$100
   Roche to Conduct a Trial on Anti-Cancer Antibody TB-403.....II-67
Mersana Therapeutics Inks License Agreement With Teva.....II-67
Acceleron Publishes Pre-clinical Data Study on ACE-041.....II-67
1$100
   Antisense Raises Capital to Continue Phase III Trabedersen Trial.....II-68
GSK Receives Positive Opinions from EMEA for Two Cancer Medicines.....II-68
EMEA Issues Positive Opinion on GSK’s Votrient.....II-68
EMEA Issues Positive Opinion on GSK’s Anti Cancer Drug Candidate, Tyverb.....II-68
1$100
   Abbott Enters into Licensing Agreement with Pierre Fabre.....II-69
Arno Therapeutics Inks Global Licensing Agreement with OSU.....II-69
BI Initiates Late Stage Clinical Trials for Two Oncology Drug Candidates.....II-69
1$100
   AnGes Obtains US FDA Approval for Phase III Trial of Collategene™.....II-70
Silence Therapeutics and Intradigm Merge.....II-70
Mersana Launches First Phase of XMT-1107 Clinical Trial.....II-70
1$100
   ImClone Receives Complete Response Letter for Erbitux® sBLA From FDA.....II-71
Oxigene Releases Encouraging Data from OXi4503 Pre-clinical Studies.....II-71
1$100
   Potentia Enters into Licensing and Purchase Option Deal with Alcon.....II-72
Quark Receives Additional Patents for RTP 801 Gene Targeting Compounds.....II-72
1$100
   Simcere Enters into Collaboration Deal with OSI Pharmaceuticals.....II-73
Pfizer Acquires Wyeth in Cash & Stock Merger.....II-73
Gene Signal Releases Interim Results from Phase II Study on GS-101.....II-73
1$100
   Onco to Conduct Second Phase Trial of Fuso's OTS102.....II-74
Green Cross Obtains US FDA Approval for Greenstatin Clinical Trial.....II-74
OXiGENE Acquire Symphony ViDA.....II-74
1$100
   Roche Releases Positive Results from Phase III Trial of Lucentis.....II-75
Pfizer Halts Phase III Sutent Study for Colorectal Cancer.....II-75
Morphotek Obtains FDA Clearance for MORAb-004 IND Application.....II-75
GlaxoSmithKline Files MAA for Pazopanib in EU.....II-75
1$100
   Roche Acquires Genentech.....II-76
Fuso Commences Phase II/III Clinical Trail for OTS102.....II-76
1$100
   EntreMed to Funnel Resources on ENMD-2076 Development.....II-77
OmegaGenesis Enters Into Collaboration with Mayo Clinic for Angiogenesis
  Research.....II-77
Eli Lilly Acquires ImClone Systems.....II-77
EntreMed Demonstrates Antitumor Effects of ENMD-2076.....II-77
1$100
   EntreMed Collaborates with JSB for ENMD-2076 Business Development.....II-78
Circadian Technologies Limited Acquires Vegenics.....II-78
Fuso and OTS to Initiate Phase II Trial for OTS102.....II-78
EntreMed Releases Pre-Clinical Findings of ENMD-2076 in Multiple Myeloma.....II-78
1$100
   Merck Serono Inks Development and Licensing Agreement with Bionomics.....II-79
Roche Inks Licensing Agreement with ThromboGenics and BioInvent for TB-403.....II-79
1$100
   Aida Initiates Pre-Clinical Development of New Anti-Cancer Drug.....II-80
Cyclacel Pharmaceuticals Releases Pre-Clinical Data of CYC116.....II-80
1$100
   Astellas and CoMentis Ink Agreement to Develop and Commercialize Beta- Secretase
  Inhibitors.....II-81
Kringle Pharma’s NK4 Receives Patent Approval in Japan.....II-81
UCB Releases Phase II Results of CDP791 in NSCLC Treatment.....II-81
Celgene Takes Over Pharmion.....II-81
1$100
   REVLIMID® Obtains Orphan Drug Designation in Japan.....II-82
TRACON Commences Phase I Clinical Trial on TRC105.....II-82
Ark Therapeutics to Acquire Lymphatix.....II-82
Access Takes Over Somanta.....II-82
1$100
   Pfizer Takes Over CovX.....II-83
Callisto Restructures Licensing Agreement with Genzyme for Atiprimod.....II-83
EntreMed Receives FDA Approval for ENMD-2076 IND Application.....II-83
1$100
   EC Grants Orphan Medicinal Status to REVLIMID for Treatment of CLC.....II-84
Bristol-Myers Squibb Snaps Up Adnexus Therapeutics.....II-84
Morvus Takes Over Two Companies.....II-84
1$100
   Merck Inks Agreement with BMS and ImClone for Erbitux® Development And
  Commercialization.....II-85
FDA Issues a Safety Labeling Update for Bevacizumab Drug.....II-85
1$100
   Fuso Initiates Phase I Clinical Study for OST102 Angiogenesis Inhibitor.....II-86
CRC to Support Bionomics in BN069 Development.....II-86
Peregrine Secures Licensing Rights for B2GP1 Angiogenesis Inhibitor.....II-86
AnGes’s Angiogenesis-Stimulating Drug Meets Primary End-Point in Phase III
  Study.....II-86
ImClone Annuls Development Agreement with UCB.....II-86
1$100
   ArQule Partners with Kyowa Hakko in Cancer Compound.....II-87
Samaritan Snaps Up Metastatin Pharmaceuticals.....II-87
EU Approves €2 Million Grants for VASOPLUS Consortium.....II-87
MGH Cancer Center Reports Results of AZD2171 Phase II Trial.....II-87
1$100
   AVEO Inks Exclusive Licensing Agreement with Kirin for Novel Anti-Cancer
  Compound.....II-88
Sangamo and Edwards Ink Angiogenesis Asset Purchase Agreement.....II-88
Covalon Secures Perfusion’s Gene Therapy Solutions.....II-88
Vical Strengthens Angiogenesis and Poloxamers IPR Portfolio.....II-88
1$100
   Biomira Takes Over ProIX Pharmaceuticals.....II-89
FDA Gives Out Warning on Bevacizumab Drug.....II-89
Athenagen Merges with Zapaq.....II-89
Tigris Secures Global Licensing Rights to Develop and Commercialize New Cancer
  Therapies.....II-89
1$100
   Bayer Yakuhin Files Marketing Application for Nexavar in Japan.....II-90
Athenagen Purchases Assets of Osprey Pharmaceutical.....II-90
Amgen Acquires Abgenix.....II-90
Genmab Enters Exclusive Licensing Agreement with Bionomics.....II-90
1$100
   OSI Pharmaceuticals Acquires Eyetech Pharmaceuticals.....II-91
FDA Changes Labeling of Iressa, Limiting Use to NSCLC.....II-91
Schering AG and Novartis Signs a Agreement to Commercialize Angiogenesis Inhibitor,
  PTK787.....II-91
1$100
   Bausch & Lomb Signs an Option Agreement with PTC Therapeutics.....II-92
Bausch & Lomb Receives License from Cephalon, Inc.....II-92
Pharmacopeia Signs a Licensing Agreement with Allergan.....II-92
Xantos Biomedicine and Cryptome Enters into Licensing Agreement.....II-92
EntreMed Receives US Patent.....II-92
1$100
   Abbott Laboratories (USA).....II-93
Adnexus Therapeutics, Inc. (USA).....II-93
Æterna Zentaris Inc. (Canada).....II-93
1$100
   Amgen, Inc. (USA).....II-94
Angstrom Pharmaceuticals Inc. (USA).....II-94
1$100
   AstraZeneca Plc. (UK).....II-95
Bayer HealthCare AG (Germany).....II-95
1$100
   Callisto Pharmaceuticals, Inc. (USA).....II-96
Celgene Corporation (USA).....II-96
1$100
   Celltech Group Plc. (UK).....II-97
Cephalon Inc. (USA).....II-97
Eisai Inc. (USA).....II-97
Eli Lilly And Company (USA).....II-97
1$100
   ImClone Systems Inc. (USA).....II-98
EntreMed Inc. (USA).....II-98
1$100
   GenVec Inc. (USA).....II-99
Genzyme Corp. (USA).....II-99
1$100
   GlaxoSmithKline Plc (UK).....II-100
Merck KGaA (Germany).....II-100
1$100
   Novartis (Switzerland).....II-101
OSI Pharmaceuticals, Inc. (USA).....II-101
1$100
   Eyetech, Inc. (USA).....II-102
Pfizer Inc. (USA).....II-102
1$100
   Progen Industries (Australia).....II-103
Regeneron Pharmaceuticals.....II-103
1$100
   Roche (Switzerland).....II-1041$100
   Genentech Inc. (USA).....II-1051$100
   Chugai Pharmaceutical Co. Ltd. (Japan).....II-1061$100
   Silence Therapeutics.....II-107
ThromboGenics Limited (Ireland).....II-107
1$100
   Table 5: World Recent Past, Current & Future Analysis for Angiogenesis Inhibitors & Stimulators by Geographic Region/Country – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart).....II-1081$350
   Table 6: World Historic Review for Angiogenesis Inhibitors & Stimulators by Geographic Region/Country – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1091$350
   Table 7: World 15-Year Perspective for Angiogenesis Inhibitors & Stimulators by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....II-1101$350
   Table 8: World Recent Past, Current & Future Analysis for Angiogenesis Inhibitors by Geographic Region/ Country – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1111$350
   Table 9: World Historic Review for Angiogenesis Inhibitors by Geographic Region / Country – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1121$350
   Table 10: World 15-Year Perspective for Angiogenesis Inhibitors by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....II-1131$350
   Table 11: World Recent Past, Current & Future Analysis for Angiogenesis Stimulators by Geographic Region/Country – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1141$350
   Table 12: World Historic Review for Angiogenesis Stimulators by Geographic Region / Country – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1151$350
   Table 13: World 15-Year Perspective for Angiogenesis Stimulators by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....II-1161$350
   A. Market Analysis.....III-1
Angiogenic Inhibitors.....III-1
List of FDA Approved Anti-Angiogenic Drugs.....III-1
1$75
   Pipeline Status By Disease.....III-2
Anti-Angiogenesis Therapeutics In Phase III Development for Renal Cell Carcinoma:
  As of 2010.....III-2
1$75
   Anti-Angiogenesis Therapeutics In Phase III Development for Breast Cancer
  Treatment: As of 2010.....III-3
Angiogenesis Stimulators.....III-3
1$75
   Historical Market Snapshots.....III-41$75
   Market Influencers.....III-5
Types of Drug Approvals.....III-5
New Drug Approval (NDA).....III-5
Orphan Drug Act.....III-5
Benefits Derived on Successful Grant of Orphan Drug Status.....III-5
Angiogenesis Foundation.....III-5
Key Role of the Foundation in Angiogenesis.....III-5
1$75
   The Rising Concern.....III-6
Cancer.....III-6
Cancer Statistics in US.....III-6
A Picture of Colon Cancer in the US.....III-6
Pancreatic Cancer.....III-6
1$75
   Vital Statistics.....III-7
Table 14: New Cancer Cases in the US By Affected Site: 2009.....III-7
2$200
   Table 15: New Cancer Cases in Males in US by Leading Site: 2009 (includes corresponding Graph/Chart).....III-91$200
   Table 16: New Cancer Cases in Females in US by Leading Site:2009 (includes corresponding Graph/Chart).....III-101$200
   Table 17: Cancer Related Deaths in the US By Affected Site:2009.....III-112$200
   Table 18: Cancer Related Deaths in Males in US by Leading Site: 2009 (includes corresponding Graph/Chart).....III-131$200
   Table 19: Cancer Related Deaths in Females in US by Leading Site: 2009 (includes corresponding Graph/Chart).....III-14
AMD and DME Incidence in the US.....III-14
1$200
   Rheumatoid Arthritis: Another Emerging Threat.....III-15
Diabetic Retinopathy.....III-15
Coronary Artery Disease (CAD).....III-15
Myocardial Infarction Statistics in the US.....III-15
Peripheral Arterial Disease.....III-15
1$75
   B. Market Analytics.....III-16
Table 20: The US Recent Past, Current & Future Analysis for Angiogenesis Inhibitors & Stimulators by Product Segments–Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2015 (includes corresponding Graph/Chart).....III-16
1$200
   Table 21: The US Historic Review for Angiogenesis Inhibitors & Stimulators by Product Segments– Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-171$200
   Table 22: The US 15-Year Perspective for Angiogenesis Inhibitors & Stimulators by Product Segments – Percentage Breakdown of Dollar Sales for Angiogenesis Inhibitors & Stimulators for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....III-181$200
   A. Market Analysis.....III-19
Angiogenesis Market – A Historic Perspective.....III-19
Cancer Trends.....III-19
1$75
   Table 23: Cancer Incidence in Europe by Site (2009) (includes corresponding Graph/Chart).....III-201$200
   B. Market Analytics.....III-21
Table 24: European Recent Past, Current & Future Analysis for Angiogenesis Inhibitors & Stimulators by Product Segments–Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-21
1$200
   Table 25: European Historic Review for Angiogenesis Inhibitors & Stimulators by Product Segments – Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-221$200
   Table 26: European 15-Year Perspective for Angiogenesis Inhibitors & Stimulators by Product Segments – Percentage Breakdown of Dollar Sales for Angiogenesis Inhibitors & Stimulators for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....III-231$200
   A. Market Analysis.....III-24
Japanese Market.....III-24
Quest for New Opportunities.....III-24
1$75
   B. Market Analytics.....III-25
Table 27: Rest of World Recent Past, Current & Future Analysis for Angiogenesis Inhibitors & Stimulators by Product Segments–Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....III-25
1$200
   Table 28: Rest of World Historic Review for Angiogenesis Inhibitors & Stimulators by Product Segments – Angiogenesis Inhibitors and Angiogenesis Stimulators Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....III-261$200
   Table 29: Rest of World 15-Year Perspective for Angiogenesis Inhibitors & Stimulators by Product Segments – Percentage Breakdown of Dollar Sales for Angiogenesis Inhibitors & Stimulators for Years 2003, 2011 and 2017 (includes corresponding Graph/Chart).....III-271$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com